Corry David B, Kheradmand Farrah
Departments of Medicine and Immunology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
J Allergy Clin Immunol. 2006 Feb;117(2 Suppl Mini-Primer):S461-4. doi: 10.1016/j.jaci.2005.09.001.
Among the asthma clinical trials published over the last several years, a unique subset has focused on novel means for inhibiting the airway inflammation that is believed to cause airway obstruction in many patients. Such interventions, broadly considered here as immune-modifying or immunomodulatory therapies, include several new drugs (omalizumab, suplatast tosilate, anti-cytokine antibodies, soluble receptors, and recombinant cytokines) and bacterial extracts. In this chapter we review the major findings with these clinical trials and indicate which have changed the management of asthma, which have not, and those that deserve further study.
在过去几年发表的哮喘临床试验中，有一个独特的子集专注于抑制气道炎症的新方法，这种炎症被认为在许多患者中会导致气道阻塞。这里广义上被视为免疫调节或免疫修饰疗法的此类干预措施包括几种新药（奥马珠单抗、甲苯磺酸舒普拉泰、抗细胞因子抗体、可溶性受体和重组细胞因子）以及细菌提取物。在本章中，我们回顾这些临床试验的主要发现，并指出哪些改变了哮喘的治疗方法，哪些没有，以及哪些值得进一步研究。
